BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, has entered a collaboration with Merck to apply the company’s technology to design candidates for up to three drug discovery programs.
BigHat’s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions…
After Pfizer, AstraZeneca, Teva and Merck KGaA backed an Israeli startup incubator looking to wield artificial intelligence in the discovery and development of new drugs, they’re now celebrating th | Pfizer, AstraZeneca, Teva and Merck KGaA have backed an Israeli startup incubator looking to wield AI programs in the discovery and development of new drugs, and now they’re celebrating the…